Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Business Insights | Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships

Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships

In recent years, alliances between pharma and biotech companies have become common, with hundreds of relationships currently in place for drug developments across virtually all high priority conditions. Such alliances are of significant benefit to pharma companies who are aiming to combat the increasing need for new product development and rapidly escalating R&D costs. For biotechs, alliances provide crucial funding that can help to maintain and expand R&D activities. These synergistic benefits have resulted in over 30% of drugs in clinical trials now being a direct product of pharma-biotech alliances. However, poor deal structure and implementation continue to contribute to the failure of almost half of these relationships. ‘Successful Pharma-Biotech Alliance Strategies’ is a new report published by Business Insights that examines the current landscape for pharma-biotech alliances and provides an in-depth analysis of the underlying factors that can determine their success or failure. Recent major joint ventures, acquisitions and licensing deals are evaluated and the latest trends and developments affecting alliance management are assessed. This report also performs a detailed examination of 9 case studies that profile varying approaches to deal structuring and relationship management, in addition to charting the current and future alliance activities of the top ten pharmaceutical companies. Volume and value forecasts for pharma-biotech deals to 2015 are also provided. Improve the effectiveness of your alliance strategies with this report’s detailed examination of the key issues influencing the success of relationships and a case study analysis of major recent alliances.

Septmebr 2008 Format PDF
Table of Contents
Price: $3,835.00 / €2,565.62

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions